What factors contribute to proteome heterogeneity in blood especially in cancer?
Best insight from top research papers
Proteome heterogeneity in cancer, particularly in blood, is influenced by various factors. Tumor heterogeneity within solid malignancies, including the presence of non-tumor cellular populations like immune cells, significantly impacts proteomic diversity . Additionally, the dynamic changes in gene and protein expression within colorectal tumors, both intratumor and intertumor, contribute to proteome heterogeneity in cancer . Epigenetic modifications, such as DNA methylation and histone remodeling, can lead to the emergence of multiple phenotypic states, wider kinetic distributions, and increased protein concentration fluctuations, further enhancing cancer heterogeneity at the molecular level . Integrating multi-omic datasets through methods like Multi-Omics Factor Analysis (MOFA) can uncover hidden sources of variation, shedding light on the complex proteomic landscape in cancer, including blood-related malignancies .
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
30 Citations | Epigenetic factors like DNA methylation and histone modifications, along with slower protein regulation compared to synthesis and degradation, contribute to proteome heterogeneity in cancer blood samples. |
| Tumour proteome heterogeneity in blood, particularly in cancer, is influenced by the complex interplay of tumour and non-tumour cellular populations, reflecting the intricate tumour microenvironment. | |
| Proteome heterogeneity in blood, especially in cancer, is influenced by dynamic changes in gene and protein expression, tumor subtypes, and variations between primary and metastatic sites. | |
| Single-cell proteomics reveals diverse protein fluctuations in cancer cells, influencing proliferation, metastasis, and therapy resistance. This heterogeneity impacts cancer progression and treatment outcomes in blood samples. | |
| Multi-Omics Factor Analysis (MOFA) identifies factors driving proteome heterogeneity in blood cancer, including known factors like IGHV status and novel factors like response to oxidative stress. |
Related Questions
Cancer and treatment response heterogeneity5 answersCancer is a highly heterogeneous disease, and treatment response heterogeneity is a common challenge in clinical practice. Various forms of heterogeneity, including cellular, genetic, molecular, spatial, temporal, and vascular heterogeneity, can influence treatment outcomes in cancer patients. In metastatic castration-resistant prostate cancer (mCRPC), intra-patient tumor heterogeneity has been observed, and it can impact treatment response and evaluation. Similarly, in colorectal cancer, spatiotemporal response heterogeneity across metastases and organ-specific response have been found to be informative for drug efficacy and patient survival. In lung adenocarcinoma, tumor response heterogeneity has been quantitatively assessed, and high heterogeneity scores have been associated with poor progression-free survival and overall survival. In breast cancer, intratumoral heterogeneity on pretreatment MRI scans has been shown to be valuable for predicting treatment response to neoadjuvant chemotherapy. Overall, understanding and addressing treatment response heterogeneity is crucial for improving patient outcomes in cancer treatment.
Cancer research using proteomics for medical biotechnology5 answersCancer research using proteomics has made significant strides in understanding the disease and improving clinical management. Proteomics technologies have been used for diagnostic and prognostic categorization of cancer, real-time monitoring of treatment, assessing drug efficacy and toxicity, and personalized medication. Proteomic technologies, such as mass spectrometry and reverse phase protein arrays, are indispensable for drug discovery, identifying potential biomarkers, and understanding protein binding hot spots. Integrating proteomics with other omics data provides extensive molecular information and can be analyzed through bioinformatic pipelines. Proteomics has also contributed to the identification of genomic aberrations, mutational changes, and signaling pathways, leading to personalized approaches in cancer treatment. Recent advances in mass spectrometry-based technologies have enabled the rapid and efficient identification of actionable therapeutic options for cancer patients. Overall, cancer research using proteomics has improved our understanding of the disease and has the potential to transform translational medicine in the field of oncology.
Why occurs tumor heterogeneity?3 answersTumor heterogeneity occurs due to genetic instability, changes in genomic sequences, and complex cellular interactions among various cell types. This heterogeneity can exist at multiple levels, including within an individual tumor, within an individual patient, among subtypes of a specific type of cancer, or within cancers originating from different tissues. The microenvironment, immune responses, and administered therapies can further alter tumor heterogeneity. Tumor heterogeneity plays a significant role in the interactions between immune cells and tumor cells, impacting the associations and potential for immune-mediated cancer control. Additionally, tumor heterogeneity is a major cause of drug resistance, leading to therapeutic failure. It can directly affect therapeutic targets and shape the tumor microenvironment, influencing drug resistance and patient prognosis. Tumor heterogeneity evolves spatially and temporally during tumor development, contributing to the constant reprogramming of the tumor microenvironment.
Implications of blood proteins regarding the low-abundance proteome ?5 answersBlood proteins play a crucial role in the low-abundance proteome analysis. Techniques such as continuous elution electrophoresis and high-performance liquid chromatography (LC) tandem mass spectrometry (MS) have been used to separate and analyze low-abundance proteins in blood samples. These techniques help remove high-abundance proteins that can mask the expression of low-abundance proteins, allowing for a more accurate detection and evaluation of biomarkers. The analysis of low-abundance proteins in blood can provide valuable information for the diagnosis and treatment of various diseases, including gout and chronic kidney disease. Additionally, the development of integrated nanoproteomics methods, such as coupling peptide-functionalized superparamagnetic nanoparticles with top-down mass spectrometry, has enabled the enrichment and comprehensive analysis of low-abundance proteins directly from serum. These advancements in blood proteome analysis offer new opportunities for studying biomarkers and gaining a deeper understanding of protein functions.
What are the molecular mechanisms that underlie the heterogeneity of metastatic breast cancer?5 answersBreast cancer cells exhibit heterogeneity due to various molecular mechanisms. These mechanisms include altered pathway signaling, chromosome instability, aneuploidy, and the repression of tumor suppressor genes while inducing oncogene activities. The plasticity and heterogeneity of cancer cells play critical roles in metastasis, but the precise underlying molecular mechanisms remain elusive. Cancer stem cells (CSCs) are a major source of heterogeneity in breast cancer, and markers such as CD24-CD44+ and ALDH+ label different BCSC populations. The tumor microenvironment (TME) also contributes to heterogeneity, with different molecular subtypes of breast cancer showing differential expression of immune markers, fibroblast markers, and angiogenesis-related markers. The TME, consisting of tumor cells and various stromal components, interacts with cancer cells to promote heterogeneity and disease progression. Overall, the heterogeneity of metastatic breast cancer is driven by a combination of genetic alterations, CSC populations, and interactions with the TME.
What is the 2023 research gap in plasma proteiomics for leukaemia and solid cancer?2 answersPlasma proteomics research in leukaemia and solid cancer has identified potential biomarkers for early detection and understanding of disease mechanisms. However, there is a research gap in the identification of plasma protein markers for predicting relapse after tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukaemia (CML) patients. Additionally, there is a need for high-resolution proteomic instrumentation to monitor protein changes in cancer and improve sensitivity and reproducibility. Furthermore, there is a lack of transfer studies in the medical education literature, which hinders the application of knowledge and skills learned in one context to real-life clinical situations. In the case of extramedullary plasma cell cancers, such as plasma cell leukaemia (PCL) and multiple extramedullary plasmacytomas (MEP), there is a need for clinical and translational research to improve understanding of disease biology and develop novel therapeutics. Finally, the transition to a circular economy in the context of sustainable consumption and production of resources through re-using and re-cycling requires further research on systemic drivers like the bio-economy.